Luis
Bujanda Fernández de Piérola
Centro de Investigación Médica Aplicada
Pamplona, EspañaPublicacións en colaboración con investigadores/as de Centro de Investigación Médica Aplicada (9)
2022
-
Targeting NAE1-mediated protein hyper-NEDDylation halts cholangiocarcinogenesis and impacts on tumor-stroma crosstalk in experimental models
Journal of Hepatology, Vol. 77, Núm. 1, pp. 177-190
2020
2019
-
Clinical presentation, diagnosis and staging of cholangiocarcinoma
Liver International, Vol. 39, Núm. S1, pp. 98-107
-
Non-parenchymal TREM-2 protects the liver from immune-mediated hepatocellular damage
Gut, Vol. 68, Núm. 3, pp. 533-546
-
Serum Metabolites as Diagnostic Biomarkers for Cholangiocarcinoma, Hepatocellular Carcinoma, and Primary Sclerosing Cholangitis
Hepatology, Vol. 70, Núm. 2, pp. 547-562
2018
-
The search for novel diagnostic and prognostic biomarkers in cholangiocarcinoma
Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1864, Núm. 4, pp. 1468-1477
2014
-
Genome-wide analysis of the human p53 transcriptional network unveils a lncRNA tumour suppressor signature
Nature communications, Vol. 5, pp. 5812
2012
-
Pravastatin inhibits cell proliferation and increased MAT1A expression in hepatocarcinoma cells and in vivo models
Cancer Cell International, Vol. 12
-
Up-regulation of microRNA 506 leads to decreased Cl -/HCO 3 - anion exchanger 2 expression in biliary epithelium of patients with primary biliary cirrhosis
Hepatology, Vol. 56, Núm. 2, pp. 687-697